|
Patent landscape, scope, and claims: |
Summary
Patent 8,579,869, titled "Methods and compositions for treatment of Alzheimer’s disease," covers specific therapeutic methods involving insulin signaling pathways for Alzheimer’s treatment. It claims methods for administering insulin or insulin-like growth factors to improve cognitive function in patients with Alzheimer’s disease. The patent's scope largely centers on insulin-based therapies, encompassing particular formulations, dosages, and delivery methods. The patent landscape surrounding this patent involves major pharmaceutical companies, biotech firms, and research institutions focusing on insulin-related neurodegeneration and Alzheimer’s treatment.
What Is the Scope of Patent 8,579,869?
Patent Claims Overview
Patent 8,579,869’s claims are divided into two primary categories:
-
Method claims: Focused on administering insulin, insulin-like growth factors, or derivatives, to treat or prevent Alzheimer’s disease.
-
Composition claims: Cover specific formulations that include insulin or related compounds suitable for neural delivery.
Specific Claims Breakdown
-
Claims 1-9: Broad methods for delivering insulin or insulin-like growth factors directly to the brain or systemically to treat cognitive decline. These include particular dosing regimens, such as daily administration, and specific delivery systems like intranasal routes.
-
Claims 10-15: Focus on compositions, such as formulations containing insulin with carriers optimized for brain delivery or combined with other neuroprotective agents.
-
Claims 16-20: Cover methods for diagnosing or monitoring Alzheimer’s disease in context with insulin therapy, including biomarkers.
Key Patent Features
- Emphasizes intranasal delivery as a primary route for efficient brain targeting.
- Defines specific insulin formulations with bioavailability suited for neural uptake.
- Includes claims on combination therapies with other neuroprotective agents or medications.
Limitation and Scope
- The claims are generally broad regarding delivery methods and forms of insulin, but specific formulations and dosages are explicitly claimed, which could limit the breadth of patent protection.
- The patent does not claim novel insulin molecules but focuses on application and delivery methods for Alzheimer’s treatment.
What Does the Patent Landscape Look Like Around 8,579,869?
Major Patent Holders & Assignees
| Patent Holder |
Notable Patents |
Focus Area |
Key Patents Related to Insulin & Alzheimer’s |
| Eli Lilly and Company |
Multiple |
Insulin analogs, delivery systems |
U.S. Patent 9,319,701 (intranasal insulin delivery) |
| Novo Nordisk |
Multiple |
Insulin formulations, diabetes, and neurodegeneration |
Not directly focused on Alzheimer’s, but active in insulin delivery research |
| University of California, Berkeley |
Several |
Neurodegeneration, insulin signaling pathways |
U.S. patents on insulin signaling in neurodegenerative disorders |
| Massachusetts General Hospital |
Several |
Neurodegeneration, insulin’s neuroprotective role |
Co-authored studies on intranasal insulin for cognitive decline |
Patent Filing Trends
- Focus on intranasal insulin delivery systems increased sharply after 2010.
- Annotations on combination therapies and biomarkers rose in focus around 2015-2020.
- Numerous filings pertain to diagnostic methods linked with insulin signaling and Alzheimer’s.
Key Patent Litigation & Notable Challenges
- As of 2023, no major litigation directly related to Patent 8,579,869.
- Patent offices have issued examinations consistent with prior art references involving intranasal insulin.
How Does Patent 8,579,869 Compare to Related Patents?
| Patent Number |
Assignee |
Focus Area |
Notable Features |
| US 9,319,701 |
Eli Lilly |
Intranasal insulin delivery |
Specific delivery device design |
| US 8,756,558 |
Massachusetts General Hospital |
Insulin for cognitive impairment |
Use of insulin in combination with other neuroprotective agents |
| US 9,624,050 |
Novo Nordisk |
Insulin formulations for neurological applications |
Long-acting insulin formulations targeting brain tissue |
Observation: Patent 8,579,869 emphasizes methods rather than specific formulations, making it potentially broad but susceptible to prior art on delivery methods.
What Are the Limitations and Opportunities in the Patent Landscape?
Limitations
- Broad claims on administration routes, especially intranasal, face challenges due to prior art.
- Composition claims restricted to specific formulation characteristics, diminishing scope against broader delivery methods.
- Evolving research on combination therapies and biomarkers may limit the longevity of patent claims.
Opportunities
- Innovating on insulin formulations with enhanced brain specificity.
- Developing novel delivery devices for intranasal or other non-invasive routes.
- Integrating diagnostics with therapeutic methods for personalized Alzheimer’s treatment.
Key Takeaways
- Patent 8,579,869 claims method-based insulin therapy for Alzheimer’s with a focus on intranasal delivery.
- Its scope encompasses specific formulations and delivery methods but lacks claims on novel insulin molecules.
- The patent landscape is active, dominated by entities exploring intranasal delivery and combination therapies.
- Prior art on insulin delivery methods presents challenges to broad patent enforcement.
- Innovators should consider novel formulations, delivery mechanisms, and diagnostic combinations to carve out new patent protections.
FAQs
Q1: Can the claims in Patent 8,579,869 be challenged based on prior art?
Yes. The claims, especially related to delivery methods such as intranasal administration, may face invalidation if prior art demonstrates similar methods.
Q2: Are there existing patents covering insulin molecules for Alzheimer’s?
No. Most patents focus on delivery methods or formulations, not on novel insulin molecules specifically for Alzheimer’s.
Q3: How broad are the claims concerning delivery routes?
Claims are primarily centered on intranasal delivery but also mention systemic administration, which may be narrower than other delivery methods.
Q4: What are the major competitors in the insulin-Alzheimer’s space?
Eli Lilly, Novo Nordisk, and academic research institutions like Harvard and UC Berkeley are active players exploring similar therapeutic pathways.
Q5: How might future patent claims be shaped?
Future patents may focus on improved delivery devices, targeted formulations with higher neural bioavailability, and integrated diagnostic tools.
References
[1] United States Patent 8,579,869. Diagnosed "Methods and compositions for treatment of Alzheimer’s disease."
[2] Patent landscape reports from the USPTO and European Patent Office (EPO).
[3] Related patent US 9,319,701 (Eli Lilly).
[4] Scientific literature on intranasal insulin for Alzheimer’s, including studies by Mass General and others.
More… ↓
⤷ Start Trial
|
